BENJANNET SUZANNE ET AL: "The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.", 13 October 2006 (2006-10-13), THE JOURNAL OF BIOLOGICAL CHEMISTRY 13 OCT 2006, VOL. 281, NR. 41, PAGE(S) 30561 - 30572, XP002506016, ISSN: 0021-9258 * see Ÿ "experimental procedures - anti PCSK9 antibodies" page 30562 * (B1)

ZHENZE ZHAO ET AL: "Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 79, no. 3, 1 September 2006 (2006-09-01), pages 514-523, XP055265231, US ISSN: 0002-9297, DOI: 10.1086/507488 (B1)

DA-WEI ZHANG ET AL: "Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation*", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 282, no. 25, 22 June 2007 (2007-06-22), pages 18602-18612, XP007912352, ISSN: 0021-9258, DOI: 10.1074/JBC.M702027200 [retrieved on 2007-04-23] (B1)

DIRK J. BLOM ET AL: "A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 19, 8 May 2014 (2014-05-08), pages 1809-1819, XP055136587, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1316222 (B1)

E. N. HAMPTON ET AL: "The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 104, no. 37, 11 September 2007 (2007-09-11), pages 14604-14609, XP055264535, US ISSN: 0027-8424, DOI: 10.1073/pnas.0703402104 (B1)

GROZDANOV PETAR N ET AL: "Expression and localization of PCSK9 in rat hepatic cells", BIOCHEMISTRY AND CELL BIOLOGY. BIOCHIMIE ET BIOLOGIE CELLULAIRE, XX, XX, vol. 84, no. 1, 1 February 2006 (2006-02-01), pages 80-92, XP008095646, ISSN: 0829-8211 (B1)

HORTON J.D., COHEN J.C & HOBBS H.H.: "PCSK9: a convertase that coordinates LDL catabolism", J. LIPID RES., vol. 50 SUPP, April 2009 (2009-04), pages S172-S177, XP002798712, (B1)

JAMIE CAMERON ET AL: "Effect of mutations in the PCSK9 gene on the cell surface LDL receptors", HUMAN MOLECULAR GENETICS, vol. 15, no. 9, 29 March 2006 (2006-03-29) , pages 1551-1558, XP055686203, ISSN: 0964-6906, DOI: 10.1093/hmg/ddl077 (B1)

LAGACE THOMAS A ET AL: "Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 116, no. 11, 1 November 2006 (2006-11-01), pages 2995-3005, XP002493243, ISSN: 0021-9738 (B1)

MAXWELL KARA N ET AL: "Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 101, no. 18, 4 May 2004 (2004-05-04), pages 7100-7105, XP002493244, ISSN: 0027-8424 (B1)

N. G. SEIDAH ET AL: "PCSK9: A Key Modulator of Cardiovascular Health", CIRCULATION RESEARCH, vol. 114, no. 6, 14 March 2014 (2014-03-14), pages 1022-1036, XP055221336, US ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.114.301621 (B1)

NI Y.G.: "A proprotein convertase subtilisin-like/Kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalisation and restores low density lipoprotein uptake", J. BIOL. CHEM, vol. 285, no. 17, 23 April 2010 (2010-04-23), pages 12882-12891, (B1)

PIPER ET AL: "The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol", STRUCTURE, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 5, 10 May 2007 (2007-05-10), pages 545-552, XP022069542, ISSN: 0969-2126, DOI: 10.1016/J.STR.2007.04.004 (B1)

RASHID S ET AL: "Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 102, no. 15, 12 April 2005 (2005-04-12), pages 5374-5379, XP002478031, ISSN: 0027-8424 (B1)

WO-A-2008/125623 (B1)

WO-A1-2009/100297 (B1)

YAN G NI ET AL: "A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo", JOURNAL OF LIPID RESEARCH, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 52, no. 1, 1 January 2011 (2011-01-01), pages 78-86, XP002686538, ISSN: 0022-2275, DOI: 10.1194/JLR.M011445 [retrieved on 2010-10-19] (B1)

CUNNINGHAM DAVID ET AL: "Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia", NAT. STRUCT. MOL. BIOL, NATURE PUBLISHING GROUP US, NEW YORK, vol. 14, no. 5, 1 May 2007 (2007-05-01), pages 413-419, XP002507497, ISSN: 1545-9993, DOI: 10.1038/NSMB1235 (B1)